NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price, Forecast & News

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) issued its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.03. The biotechnology company earned $1.78 million during the quarter, compared to analyst estimates of $4.54 million. BioCryst Pharmaceuticals had a negative net margin of 1,129.38% and a negative return on equity of 2,511.40%. View BioCryst Pharmaceuticals' Earnings History.

BioCryst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for BioCryst Pharmaceuticals.

8 Wall Street analysts have issued 1 year price targets for BioCryst Pharmaceuticals' stock. Their forecasts range from $4.00 to $15.00. On average, they anticipate BioCryst Pharmaceuticals' stock price to reach $8.93 in the next twelve months. This suggests a possible upside of 201.6% from the stock's current price. View Analyst Price Targets for BioCryst Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioCryst Pharmaceuticals.

News coverage about BCRX stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. BioCryst Pharmaceuticals earned a daily sentiment score of -1.7 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totalling 15,750,000 shares, an increase of 13.0% from the September 30th total of 13,940,000 shares. Based on an average trading volume of 1,440,000 shares, the short-interest ratio is presently 10.9 days. Approximately 14.5% of the company's shares are sold short. View BioCryst Pharmaceuticals' Current Options Chain.

Some companies that are related to BioCryst Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include El Pollo LoCo (LOCO), Idera Pharmaceuticals (IDRA), Inovio Pharmaceuticals (INO), Virtu Financial (VIRT), Advanced Micro Devices (AMD), La Jolla Pharmaceutical (LJPC), Alcoa (AA), Exelixis (EXEL), Sangamo Therapeutics (SGMO) and Macrocure (MCUR).

BioCryst Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (3.28%), Point72 Asset Management L.P. (2.20%), First Midwest Bank Trust Division (0.37%), Squarepoint Ops LLC (0.24%), Rhumbline Advisers (0.16%) and Russell Investments Group Ltd. (0.15%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Jon P Stonehouse, Kenneth B Lee Jr, Lynne Powell, Megan Sniecinski, Steve Aselage, Thomas R Staab II and William P Sheridan. View Institutional Ownership Trends for BioCryst Pharmaceuticals.

BCRX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Voloridge Investment Management LLC and First Midwest Bank Trust Division. Company insiders that have sold BioCryst Pharmaceuticals company stock in the last year include Lynne Powell, Thomas R Staab II and William P Sheridan. View Insider Buying and Selling for BioCryst Pharmaceuticals.

BCRX stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Squarepoint Ops LLC, Russell Investments Group Ltd., Public Employees Retirement System of Ohio, Redmile Group LLC, California Public Employees Retirement System, Virtu Financial LLC and Rhumbline Advisers. Company insiders that have bought BioCryst Pharmaceuticals stock in the last two years include Alane P Barnes, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski and Steve Aselage. View Insider Buying and Selling for BioCryst Pharmaceuticals.

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BCRX stock can currently be purchased for approximately $2.96.

BioCryst Pharmaceuticals has a market capitalization of $439.17 million and generates $20.65 million in revenue each year. The biotechnology company earns $-101,250,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. BioCryst Pharmaceuticals employs 100 workers across the globe.View Additional Information About BioCryst Pharmaceuticals.

The official website for BioCryst Pharmaceuticals is http://www.biocryst.com/.

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]